TickerTalks
Browse all tickers →
TickerTalks›$NVO
NVNVO

Novo Nordisk A/S

$NVO·$220B·Drug Manufacturers - General·Healthcare
$51.48+1.8%YTD-0.3%1Y-23.2%
Mentions · last 7 days
2026-07-10: 465 posts2026-07-11: 740 posts2026-07-12: 434 posts2026-07-13: 498 posts2026-07-14: 380 posts2026-07-15: 448 posts2026-07-16: 487 posts3,490+13%
Price updated 13h ago·X counts updated 12h ago
NVNVO
$NVONovo Nordisk A/S
$51.48+1.82%3.5k posts+13%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $NVO, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptAcceleratingAI verdict · as of 2026-07-17

The move is getting stronger, with heavier trading behind it.

Wegovy pill just got European approval and IQVIA data says the oral push is pulling ahead of Lilly — the reset trade is on.

Novo Nordisk is the Danish pharma giant behind Ozempic, Wegovy, and the semaglutide GLP-1 franchise that dominated 2023-2024 before losing ground to Eli Lilly on Mounjaro/Zepbound. The 2025 setback has been the base for what is now becoming a re-rating story.

What's turning:

  • The oral franchise just got its first big regulatory win: EC approval for Wegovy pill last week gives Novo a differentiated product that Lilly's oral orforglipron does not yet match in Europe — real market share to gain, not just a talking point.
  • The prescription data validates the launch: IQVIA weekly TRx has Oral Wegovy at 153,050 (+2.4% WoW) vs Foundayo's 'muted' launch per Jefferies — real prescriber pull, not just marketing spend.
  • The multiple is finally reasonable: 10.3x trailing earnings and roughly 12x FY27 EPS consensus is the cheapest Novo has traded in years despite margins that would make most drug companies weep (gross margin 82%, operating margin 45%).
  • The channel expansion is broader than just Europe: China's Essential Medicines List adding semaglutide, and NVO stepping up UK public-awareness campaigns — every incremental country that gets access is a distinct catalyst the Street underweights.

The forward look: with the stock already up ~19% in the last month and analyst sentiment still 22 Hold / 3 Sell against just 12 Buys, there's real room for consensus to catch up if the August 5 Q2 print confirms the sequential ramp. Watch the Foundayo/Zepbound uptake data alongside it — if Lilly re-accelerates in the same window, the 'Novo is the cheaper GLP-1' trade gets a lot harder, and the recent run gives back quickly.

Agrees with X sentimentThe X bullish read on Oral Wegovy overtaking Foundayo lines up with the IQVIA data and this week's EC approval. Where the crowd is right: the launch is real. Where the sell-side stack (22 Hold, 3 Sell) hasn't caught up: the multiple.

What to watch: August 5 Q2 earnings, the next few IQVIA weekly reads on Oral Wegovy vs Foundayo, and any Lilly disclosure of Zepbound/orforglipron uptake — a Lilly re-acceleration is the risk that resets this trade.

On the calendar: 2026-08-05 — Q2 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment53 posts analyzed · as of 2026-07-15

Novo Nordisk chatter is dominated by the Oral Wegovy vs Eli Lilly's Foundayo prescription race. IQVIA weekly data shows Oral Wegovy pulling further ahead with 153,050 TRx (+2.4% WoW) versus Foundayo, which Jefferies described as a 'muted' launch. Boots UK reported one of its busiest customer-consultation days ever on the Wegovy pill launch, with 80% of patients new to the weight-loss service and 10% switching from injections. Chinese Essential Medicines List added semaglutide, generic launches in India face API delays, and NVO is stepping up UK public-awareness campaigns. The stock is up ~19% in the past month; analyst sentiment (12 Buy / 22 Hold / 3 Sell) is still cautious.

Read the AI verdict + X sentiment for $NVO

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes GLP-1 drugs Ozempic and Wegovy for diabetes and obesity with semaglutide driving blockbuster revenue growth.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $NVO.

Drug Manufacturers - General · Healthcare

No material change from last week — oral semaglutide versus injectable Zepbound, with Amgen, Pfizer, and AZ all presenting obesity pipeline data.

What this means for $NVO

Direct beneficiary — Makes GLP-1 drugs Ozempic and Wegovy for diabetes and obesity with semaglutide driving blockbuster revenue growth; the company is structurally positioned to capture the oral GLP-1 and obesity pipeline expansion and competition.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+17.8%YTD
+47.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
10.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
32.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
45.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
2.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
66.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
81.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 6, 2026$1.04$0.87+19.5%
Q4 2025Feb 3, 2026$1.00$0.90+11.1%
Q3 2025Nov 5, 2025$1.02$0.77+32.5%
Q2 2025Aug 6, 2025$0.97$0.93+4.3%
Next earningsWed, Aug 5·consensus EPS $0.82

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$96.8B+24.0%86.0%61.6%$10.93$12.0B
Q4 FY25$79.1B-7.6%80.9%40.1%$6.06$-36.2B
Q3 FY25$75.0B+5.1%76.1%31.6%$4.50$30.7B
Q2 FY25$76.9B+12.9%83.3%43.5%$5.96$24.5B

Forward consensus

5-year forecast · up to 16 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$292.3B$274.1B – $309.7B$21.54$19.56 – $23.6416
FY27$299.1B$290.4B – $313.5B$21.52$20.40 – $24.3516
FY28$318.9B$295.2B – $353.0B$23.24$21.00 – $26.4814
FY29$349.1B$323.2B – $386.5B$26.47$23.92 – $30.1615
FY30$366.3B$339.2B – $405.6B$27.95$25.25 – $31.8415

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.45%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+12.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+8.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 3.2B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.365-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

No material 8-K / SC 13D / S-3 / 424B5 filings in the last 180 days.

+ 52 other (44 6-Ks · 3 13Gs · 2 11-Ks · 1 SD) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Notezacks.com·16h agoNVO Stock Up on EC Approval of Wegovy Pill to Treat Obesityzacks.com·21h agoMedicare's $50 Weight-Loss Drug Window Opens In July: What Smart Enrollees Do Before 2027benzinga.com·1d agoWegovy Pill in Europe - Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drugbenzinga.com·2d agoRHHBY's Gazyva Gets FDA Priority Review for Label Expansionzacks.com·2d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LLY$JNJ$PFE$MRK$ABBV$GILD$OGN$AMGN
Voices on X · top 12 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport